Cardiovascular disease (CVD) costs the economy €210 billion per year in Europe. There is an association between low-density lipoprotein cholesterol (LDL-C) and CVD risk.
A single blind, multicenter, randomized controlled trial to evaluate the effectiveness and cost of a novel nutraceutical (LopiGLIK®) lowering cardiovascular disease risk / Manfrin, Andrea; Trimarco, Valentina; Manzi, Maria Virginia; Rozza, Francesco; Izzo, Raffaele. - In: CLINICOECONOMICS AND OUTCOMES RESEARCH. - ISSN 1178-6981. - 10:(2018), pp. 601-609-609. [10.2147/CEOR.S172838]
A single blind, multicenter, randomized controlled trial to evaluate the effectiveness and cost of a novel nutraceutical (LopiGLIK®) lowering cardiovascular disease risk
Trimarco, ValentinaMembro del Collaboration Group
;Manzi, Maria VirginiaMembro del Collaboration Group
;Rozza, FrancescoMembro del Collaboration Group
;Izzo, RaffaeleMembro del Collaboration Group
2018
Abstract
Cardiovascular disease (CVD) costs the economy €210 billion per year in Europe. There is an association between low-density lipoprotein cholesterol (LDL-C) and CVD risk.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
